VITA 34 (V3V) AI Stock Analysis

• Market Cap: €90.65M
• Dividend Yield: N/A
• Average Volume (3M): 1.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: 9.48%
• EPS Growth: -481.90%
• Country: DE
• Employees: 783
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): 0.07
• Shares Outstanding: 17,640,104
• 10 Day Avg. Volume: 2,079
• 30 Day Avg. Volume: 1,645
• PEG Ratio: -0.01
• Price to Book (P/B): 5.08
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 13.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.14
• Revenue Forecast (FY): €92.00M

• Rating: 55 Neutral
• Price Target: €5.50 ▼(-9.09% Downside)
• Action: Reiterated Date: 12/13/25
• Date: Action: Reiterated 12/13/25

The overall stock score is primarily influenced by the company's strong technical momentum, despite financial instability and poor valuation metrics. The stock's bullish trend is a significant positive, but the lack of profitability and cash flow issues weigh heavily on the score.

Positive Factors

Recurring revenue model

The subscription-like annual storage fees create a durable, predictable revenue base and high customer lifetime value. This recurring cash inflow supports long-term planning, capacity utilization and makes scaling unit economics easier as customer volumes grow over months to years.

Niche market leadership

Established specialization in umbilical cord blood storage gives structural competitive advantages: regulatory know-how, trust among families and hospital partnerships. These barriers and domain expertise sustain market share and pricing power over the medium term.

Revenue growth momentum

Material revenue expansion indicates successful customer acquisition and service uptake, supporting scale economies. If sustained, this growth can improve gross margins, spread fixed costs and provide a platform for reinvestment into product offerings and partnership expansion.

Negative Factors

High financial leverage

Elevated leverage increases fixed interest obligations and reduces financial flexibility, limiting the firm's ability to fund capex or weather cyclical slowdowns. Over months, this raises refinancing and solvency risk, particularly if cash generation does not strengthen.

Persistent unprofitability

Negative ROE and recurring net losses constrain retained earnings and limit internal funding for growth. Sustained unprofitability pressures equity value, deters investment, and forces reliance on external capital which can dilute shareholders or increase debt.

Weak cash flow conversion

Inability to convert income into cash undermines the company's capacity to service debt, invest in capacity or fund working capital from operations. Over a multi-month horizon this may necessitate costly financing, constrain growth initiatives, and elevate liquidity risk.

VITA 34 Business Overview & Revenue Model

Company Description

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

How the Company Makes Money

VITA 34 generates revenue primarily through the collection and storage services of umbilical cord blood stem cells. The company charges families a fee for the initial collection and processing of the stem cells, as well as an annual storage fee for maintaining the samples in their facility. Additionally, VITA 34 may generate revenue from partnerships with healthcare providers and hospitals, where they provide educational resources and services related to stem cell banking. Their business model is further supported by the growing demand for regenerative medicine and advancements in stem cell research, allowing them to capitalize on emerging therapies and treatments.

VITA 34 Financial Statement Overview

Summary

VITA 34 is experiencing strong revenue growth but faces significant challenges in profitability and cash flow management. High leverage and negative returns on equity suggest financial instability. The company needs to focus on improving operational efficiency and managing debt to enhance financial health and sustainability.

Income Statement

VITA 34 has shown significant revenue growth in the TTM period, with a 63.5% increase. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has improved slightly over the years but remains low compared to industry standards. The consistent negative net income highlights ongoing challenges in achieving profitability.

Balance Sheet

The company has a high debt-to-equity ratio of 1.41 in the TTM period, indicating significant leverage. Return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively low, suggesting a higher reliance on debt financing, which could pose risks if not managed properly.

Cash Flow

VITA 34's cash flow situation is concerning, with negative free cash flow growth in the TTM period. The operating cash flow to net income ratio is low, indicating challenges in converting income into cash. The negative free cash flow to net income ratio further highlights cash flow issues, which could impact the company's ability to invest in growth or service debt.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Dec 2020
Income Statement
Total Revenue	88.29M	82.18M	77.06M	68.94M	28.42M	20.07M
Gross Profit	25.41M	20.65M	28.24M	2.73M	12.44M	11.66M
EBITDA	2.89M	-443.00K	5.81M	-18.34M	949.00K	5.01M
Net Income	-9.86M	-12.14M	-1.86M	-27.39M	-3.93M	1.45M
Balance Sheet
Total Assets	159.53M	152.74M	158.36M	151.51M	177.95M	58.46M
Cash, Cash Equivalents and Short-Term Investments	13.05M	18.46M	17.42M	18.23M	35.26M	10.52M
Total Debt	19.35M	18.10M	21.57M	28.18M	32.32M	5.30M
Total Liabilities	147.28M	139.83M	135.58M	135.66M	136.00M	28.93M
Stockholders Equity	13.77M	14.13M	23.56M	16.50M	43.07M	29.55M
Cash Flow
Free Cash Flow	-386.00K	5.46M	5.06M	-10.92M	467.00K	3.33M
Operating Cash Flow	4.29M	8.65M	9.15M	-4.49M	2.73M	3.98M
Investing Cash Flow	-8.47M	-3.08M	-3.57M	-5.81M	24.87M	-252.00K
Financing Cash Flow	-1.55M	-6.09M	-5.09M	-6.27M	-4.70M	-2.43M

VITA 34 Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Negative. The current price of 6.05 is above the 20-day moving average (MA) of 5.30, above the 50-day MA of 5.71, and above the 200-day MA of 5.37, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:V3V.

VITA 34 Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LIK	73 Outperform	€153.00M	32.53	23.66%	―	0.21%	7.53%
93M1	70 Outperform	€95.47M	-0.83	-43.43%	5.31%	180.19%	-196.45%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
V3V	55 Neutral	€90.65M	-9.19	-50.39%	―	9.48%	-481.90%
MAK	41 Neutral	€19.92M	-1.49	―	―	6.87%	-94.85%